A Phase 2 interventional study of RNS and RDN in Arrhythmias, Cardiac, sponsored by Diagram B.V.. Terminated at 1 site in Netherlands. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-05-06.
Sponsored by Diagram B.V. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Arrhythmias, Cardiac with a site in Netherlands — 13 open to participants now, 18 under way, none of them phase 3. Arrhythmias, Cardiac · Netherlands.
Among the 72 studies in Arrhythmias, Cardiac with a site in Netherlands, this one is the 31st largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2015, is one of 5 in phase 2, and was the 33rd registered.
1,052 studies on the registry are indexed under Arrhythmias, Cardiac; 236 are open to participants now.
Browse Arrhythmias, Cardiac studies →13 of the 72 studies in Arrhythmias, Cardiac with a site in Netherlands are open now. Recruiting first, the newest first:
Biotronik, Inc. · Sites in Netherlands, United States, Australia and 5 more countries
Ages 18+
Cardurion Pharmaceuticals, Inc. · Sites in Netherlands, United States, Canada and 3 more countries
Ages 18–99
Novartis Pharmaceuticals · Sites in Netherlands, United States, Canada and 4 more countries
Ages 18+
Stereotaxis · Sites in Netherlands, Denmark, Lithuania and 1 more country
Ages 18+
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 167 Arrhythmias, Cardiac studies recruiting now, 119 (71%) set no upper age limit and 13 (8%) stop at 75 or younger; 31 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 8
First in 1983; this study’s year is marked. 4 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 100 across 518 interventional studies indexed under Arrhythmias, Cardiac.
Median enrollment 240 across the 33 interventional studies, 544 across the 38 observational. Of the 43 that completed or were terminated, 13 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 72 have an industry lead sponsor. The 10 most frequent:
Diagram B.V. is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Diagram B.V. has 1 study filed under Arrhythmias, Cardiac — fewer than ten, so there is no comparison to draw.
7 of the studies in Arrhythmias, Cardiac with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT05890716Idoven 1903 S.L.AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM) | 2026-12 |
| NCT04735016Medtronic Cardiac Ablation SolutionsDiamondTemp Global Registry | 2026-12-31 |
| NCT07118358Biotronik, Inc.BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | 2027-03 |
| NCT06658899Cardurion Pharmaceuticals, Inc.A Phase 2 Study of CRD-4730 in CPVT | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 72 studies in Arrhythmias, Cardiac with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Rationale:
Sympathetic activity plays an important role in the pathogenesis of ventricular tachyarrhythmia. Previous studies have shown evidence of significant heritable influences on individual responses to adrenergic stimulation. Catheter-based renal sympathetic denervation (RDN) is a novel treatment option for patients with resistant hypertension, proved to reduce local and whole-body sympathetic activity. The investigators hypothesize that percutaneous transluminal electrical stimulation of the sympathetic nerve bundles in the renal arteries will cause ventricular arrhythmias and renal denervation will suppress these arrhythmias in patients with sympathetic ventricular arrhythmias.
Objective:
This study will investigate the effects of renal nerve stimulation before and after percutaneous transluminal RDN on cardiac excitable properties including induction of ventricular tachy-arrhythmias before and after RDN in six studies, i.e. patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), long QT syndrome and arrhythmogenic right ventricular cardiomyopathy (ARVC), sympathetically driven ventricular arrhythmias, hypertrophic cardiomyopathy (HCM), dilated non-ischemic cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM). The aim of the six studies is to assess the anti-arrhythmic effects of RDN in patients with sympathetic ventricular tachy-arrhythmias.
Study design:
Investigator initiated, multi centre, six pretest-posttest design studies.
Study population:
Patients with recurrent sympathetically driven ventricular arrhythmia despite optimal pharmacological therapy. Patients should be diagnosed with CPVT and certain types of long QT syndrome, ARVC, HCM, DCM and ICM. Eligible patients will be in the age category of 18-85 year.
Intervention:
RDN will be performed according to routine clinical practice. Prior to the ablation procedure, catheter mapping of the renal arteries will be performed according to routine clinical practice. Clinical and biological responses to transluminal electrical renal nerve stimulation will be assessed before and after RDN.
Study endpoints:
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
In several studies, it was shown that RDN was safe. The intervention resulted in significantly better control of blood pressure with less medication, and beneficial changes in heart rate variability, autonomic sympathetic balance, renal arteriolar function, and a higher success of atrial fibrillation prevention. In case reports and case series, RDN had a favourable effect in patients with sympathetic drug refractory ventricular tachy-arrhythmias.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
catecholaminergic polymorphic ventricular tachycardia (CPVT) patients
Procedure: RNS and RDN
long QT syndrome patients
Procedure: RNS and RDN
arrhythmogenic right ventricular cardiomyopathy (ARVC) patients
Procedure: RNS and RDN
hypertrophic cardiomyopathy (HCM) patients
Procedure: RNS and RDN
dilated non-ischemic cardiomyopathy (DCM) patients
Procedure: RNS and RDN
ischemic cardiomyopathy (ICM) patients
Procedure: RNS and RDN
The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
Induction of ventricular arrhythmias (e.g. ventricular tachycardia and ventricular fibrillation)
Induction of ventricular arrhythmias in response to RNS prior to RDN and absence of RNS induced ventricular arrhythmias after RDN
Time frame: A few minutes before RDN RNS will be performed. Time frame before RDN: 0-10 min. after RNS and before RDN. Time frame after RDN: 0-10 min.
Development of ventricular arrhythmia
Development of ventricular arrhythmia during exercise stress testing performed 6 months after procedure/intervention
Time frame: 6 months after procedure/intervention
Time to first detection of ventricular arrhythmia or appropriate ICD therapy
Time to first detection of ventricular arrhythmia or appropriate ICD therapy with the monitoring period starting immediately after the intervention.
Time frame: procedure/intervention-12 month follow up
Changes in ventricular refractoriness (frequency)
Changes in ventricular refractoriness (frequency, beats/min) to programmed electrical stimulation in the setting of routine electrophysiological study before and directly (0-10 min) after RDN.
Time frame: procedure/intervention
Changes in ventricular refractoriness (duration)
Changes in ventricular refractoriness (duration, sec) to programmed electrical stimulation in the setting of routine electrophysiological study before and directly (0-10 min) after RDN.
Time frame: procedure/intervention
Number of ventricular arrhythmias
Inducibility (number) of ventricular arrhythmias to programmed electrical stimulation in the setting of routine electrophysiological study before and after RDN.
Time frame: procedure/intervention
Ventricular arrhythmia burden
Ventricular arrhythmia burden after 6 and 12 months of follow-up in patients with ICD or continuous rhythm monitoring with a loop recorder. The monitoring period starts immediately after the intervention.
Time frame: procedure/intervention- 6,12 months follow up
Blood pressure
Blood pressure at 6 and 12 months after the intervention
Time frame: 6-12 months follow up
Number of (Supra-)Ventricular arrhythmias induced by exercise testing
Number of (Supra-)Ventricular arrhythmias induced by exercise testing
Time frame: baseline- 6 months follow up
(Supra-)Ventricular arrhythmias response changes (frequency) induced by exercise testing
(Supra-)Ventricular arrhythmias response changes (frequency, beats/min) induced by exercise testing
Time frame: baseline- 6 months follow up
(Supra-)Ventricular arrhythmias response changes (duration) induced by exercise testing
(Supra-)Ventricular arrhythmias response changes (duration, sec) induced by exercise testing
Time frame: baseline- 6 months follow up
Changes in heart rate variability
Changes in heart rate variability measures tested by Holter monitoring compared to measurement before the intervention
Time frame: baseline- 3, 6 and 12 month follow up
Changes in prevalence of events
Changes in prevalence of events (hospital admission for VT or appropriate ICDshock) in the period of one year after intervention compared to a one year period before intervention.
Time frame: 12 month before procedure/intervention-12 month follow up
Change in blood pressure
Change in blood pressure compared to measurement before the intervention
Time frame: baseline- 6, 12 month follow up
Heart rate response changes induced by exercise testing
Heart rate response changes induced by exercise testing
Time frame: baseline- 6 months follow up
Blood pressure response changes induced by exercise testing
Blood pressure response changes induced by exercise testing
Time frame: baseline-6 months follow up
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2015 to primary completion in May 2020, 62 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Diagram B.V.